Overall, a total of 10 days of dosing for Patients A, B, and D and 12 days for Patient C, with baricitinib 4 mg once‐daily orally in Patients A, C, and D, and 2 mg in Patient B (in accordance with the label guidelines for treatment of RA), was sufficient to document in all patients improved lung function, resolution of their illness, and reductions in viral load, plasma IL‐6, ferritin, and CRP levels. Here, CRP is linked to rheumatoid arthritis.